Association Between High-Sensitivity Cardiac Troponin, Myocardial Ischemia, and Revascularization in Stable Coronary Artery Disease
Free-to-read version at publisher website
Impact and interest:
4 citations in Scopus
1 citations in Web of Science®
Search Google Scholar™
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
| ID Code: | 232203 | ||
|---|---|---|---|
| Item Type: | Contribution to Journal (Letter) | ||
| Refereed: | Yes | ||
| ORCID iD: |
|
||
| Additional Information: | Funding Information: The authors acknowledge the support of the NIHR Imperial Biomedical Research Centre and Imperial College British Heart Foundation Centre of Research Excellence. Drs Rajkumar, Wereski, and Foley are recipients of Clinical Research Training Fellowships from the Medical Research Council (MR/S021108/1, MR/V007017/1, MR/V001620/1). Dr Cullen has received research grants awarded to the Metro North Hospital and Health Service from Abbott Diagnostics, Beckman Coulter, and Siemens outside of the submitted work; and has received honoraria from Abbott Diagnostics and Siemens Healthineers. Dr Harrell Jr is supported by a Clinical and Translational Science Award [UL1 TR002243] from the National Centre for Advancing Translational Sciences; and has received consulting fees from Johnson & Johnson, Janssen, AstraZeneca, and Annexon Biosciences outside of the submitted work. Dr Mills is supported by a Chair Award, Programme Grant, and Research Excellence Award (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216) from the British Heart Foundation; has received research grants awarded to the University of Edinburgh from Abbott Diagnostics and Siemens Healthineers outside of the submitted work; and has received honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and LumiraDx. Dr Al-Lamee has received honoraria from Philips Volcano, Abbott Vascular, and Menarini Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the BHF Cardiovascular Biomarker Laboratory, University of Edinburgh, for their contribution to this work. (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina [ORBITA]; NCT02062593) | ||
| Measurements or Duration: | 3 pages | ||
| DOI: | 10.1016/j.jacc.2022.03.369 | ||
| ISSN: | 0735-1097 | ||
| Pure ID: | 110926122 | ||
| Divisions: | Current > Research Centres > Centre for Healthcare Transformation Current > Research Centres > Australian Centre for Health Services Innovation Current > QUT Faculties and Divisions > Faculty of Health Current > Schools > School of Public Health & Social Work |
||
| Funding Information: | The authors acknowledge the support of the NIHR Imperial Biomedical Research Centre and Imperial College British Heart Foundation Centre of Research Excellence. Drs Rajkumar, Wereski, and Foley are recipients of Clinical Research Training Fellowships from the Medical Research Council (MR/S021108/1, MR/V007017/1, MR/V001620/1). Dr Cullen has received research grants awarded to the Metro North Hospital and Health Service from Abbott Diagnostics, Beckman Coulter, and Siemens outside of the submitted work; and has received honoraria from Abbott Diagnostics and Siemens Healthineers. Dr Harrell Jr is supported by a Clinical and Translational Science Award [UL1 TR002243] from the National Centre for Advancing Translational Sciences; and has received consulting fees from Johnson & Johnson, Janssen, AstraZeneca, and Annexon Biosciences outside of the submitted work. Dr Mills is supported by a Chair Award, Programme Grant, and Research Excellence Award (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216) from the British Heart Foundation; has received research grants awarded to the University of Edinburgh from Abbott Diagnostics and Siemens Healthineers outside of the submitted work; and has received honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and LumiraDx. Dr Al-Lamee has received honoraria from Philips Volcano, Abbott Vascular, and Menarini Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the BHF Cardiovascular Biomarker Laboratory, University of Edinburgh, for their contribution to this work. (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina [ORBITA];NCT02062593) The authors acknowledge the support of the NIHR Imperial Biomedical Research Centre and Imperial College British Heart Foundation Centre of Research Excellence. Drs Rajkumar, Wereski, and Foley are recipients of Clinical Research Training Fellowships from the Medical Research Council (MR/S021108/1, MR/V007017/1, MR/V001620/1). Dr Cullen has received research grants awarded to the Metro North Hospital and Health Service from Abbott Diagnostics, Beckman Coulter, and Siemens outside of the submitted work; and has received honoraria from Abbott Diagnostics and Siemens Healthineers. Dr Harrell Jr is supported by a Clinical and Translational Science Award [UL1 TR002243] from the National Centre for Advancing Translational Sciences; and has received consulting fees from Johnson & Johnson, Janssen, AstraZeneca, and Annexon Biosciences outside of the submitted work. Dr Mills is supported by a Chair Award, Programme Grant, and Research Excellence Award (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216) from the British Heart Foundation; has received research grants awarded to the University of Edinburgh from Abbott Diagnostics and Siemens Healthineers outside of the submitted work; and has received honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and LumiraDx. Dr Al-Lamee has received honoraria from Philips Volcano, Abbott Vascular, and Menarini Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the BHF Cardiovascular Biomarker Laboratory, University of Edinburgh, for their contribution to this work. (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina [ORBITA]; NCT02062593 ) | ||
| Copyright Owner: | 2022 by the American College of Cardiology Foundation | ||
| Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||
| Deposited On: | 06 Jun 2022 00:54 | ||
| Last Modified: | 30 May 2024 17:37 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)